MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits

MPR Drug News

Rapid Reversal Seen With Idarucizumab in Pradaxa-Treated Patients

Boehringer Ingelheim presented positive results of its Phase 3 RE-VERSE AD study for idarucizumab as a reversal agent for the anticoagulant effect of Pradaxa (dabigatran) in patients needing emergency surgery or for life-threatening or uncontrolled bleeding events.

Positive Phase 3 Results for New Cholesterol Tx Presented

Regeneron and Sanofi announced new positive results for Praluent (alirocumab) from the Phase 3 ODYSSEY clinical trial program in heterozygous familial hypercholesterolemia (HeFH) patients.

Elotuzumab BLA Given Priority Review for Multiple Myeloma

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Empliciti (elotuzumab, Bristol-Myers Squibb/AbbVie) for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies.

Fewer Side Effects Seen With Half-Dose Diuretic Combo vs. Single Diuretic

Results from the PATHWAY 3 study demonstrated that a combination of half-dose diuretics can significantly reduce blood pressure without the adverse effects associated with full doses of either diuretic alone, as reported at the European Society of Cardiology Congress 2015.

Newer Genetic Testing Technologies May Help Autism Dx in Children

Newer genetic tests like chromosomal microarray analysis and whole-exome sequencing for children with autism spectrum disorder (ASD) may help detect genetic mutations potentially associated to the disorder, a study published in JAMA reported.